Document is current
Any future updates will be listed below
-
Authors
Grahnemo, Louise https://orcid.org/0000-0001-5276-6612
Kambur, Oleg
Lahti, Leo https://orcid.org/0000-0001-5537-637X
Jousilahti, Pekka https://orcid.org/0000-0001-7190-0979
Niiranen, Teemu
Knight, Rob
Salomaa, Veikko https://orcid.org/0000-0001-7563-5324
Havulinna, Aki S. https://orcid.org/0000-0002-4787-8959
Ohlsson, Claes https://orcid.org/0000-0002-9633-2805
- License Information
-
More Information
Article History
Received: 8 January 2024
Accepted: 9 July 2024
First Online: 14 August 2024
Competing interests
: C.O. is an applicant on filed patent applications on the effect of probiotics on bone metabolism. V.S. has had research collaboration with Bayer, Ltd (unrelated to the present study). R.K. is an advisor to DayTwo, Ltd.; an advisor to and equity holder of GenCirq, Inc., BiomeSense, Inc., and Cybele Microbiome, Inc.; co-founder and equity holder of Biota Technology, Inc.; and a co-founder, advisor, and equity holder of Micronoma, Inc. R.K. is also the director of UCSD Center for Microbiome Innovation, and as an invited speaker, he has been compensated by the International Human Microbiome Consortium Congress, Tulso Biotechnology Co., Ltd., Royal Swedish Academy of Science, and Uehara Memorial Foundation in the past 12 months.
